1 Recent studies indicate that nitroglycerin (NTG) can produce bene®cial clinical eects in healing anal ®ssures through the relaxation of the internal anal sphincter. The in vivo relaxation eects of NTG on the anorectal smooth muscle have not been studied and it is not known whether this tissue may also exhibit pharmacological tolerance toward NTG. 2 We have developed an in vivo procedure in the anaesthetized rat that permits continual monitoring of anorectal pressure after intravenous (i.v.) and intra-rectal application of NTG. The relaxant eects of NTG were quanti®ed via the area-under-the-contraction-waveforms vs time curve (AUEC). 3 AUEC decreased signi®cantly after intra-rectal bolus doses of NTG (5 ± 25 mg), in a dose-and time-dependent manner. Sustained relaxation eects on anorectal pressure were also observed after continuous intra-rectal infusions of NTG. 4 Two-hours of i.v. NTG infusion led to a signi®cant reduction in the mean arterial blood pressure (MAP) response toward a i.v. NTG (30 mg) bolus challenge. In contrast, relaxation of the anorectal pressure toward the challenge dose was not altered after NTG infusion. 5 In isolated tissues, cyclic GMP accumulation was signi®cantly decreased after NTG preincubation in the rat aorta but not in the rat anorectal smooth muscle and anal sphincter. 6 These results indicate that the relaxation response toward NTG was not diminished in the anorectum under conditions that produced vascular tolerance. Thus, NTG causes signi®cant and sustained in vivo relaxation of anorectal smooth muscle in the anaesthetized rat without evidence of tolerance development.
Introduction
Organic nitrates, such as nitroglycerin (NTG), have long been used in treating cardiovascular disease because of their potent relaxation eects on the vascular smooth muscle. These eects were generated by in vivo metabolic conversion of these compounds to nitric oxide (NO), which stimulates the production of cyclic GMP, leading to vascular relaxation (Fung et al., 1992; Munzel et al., 1996) . Recent studies suggest that NO is also released as an important mediator from enteric inhibitory neurons innervating the internal anal sphincter muscle, contributing to the relaxation of this tissue (Rattan & Chakder, 1997; Stebbing, 1998) . Since internal anal sphincter hypertonia may play an important role in disease states such as anal ®ssure and anal pain caused by external haemorrhoids, it is not surprising that organic nitrates have been shown to exert a bene®cial eect in treating these disease conditions (Gor®ne, 1995a,b; Lysy et al., 1998) .
One of the major drawbacks of NTG therapy in cardiovascular disease is the rapid development of pharmacological tolerance, both in vitro and in vivo Munzel et al., 1996) . The mechanisms for this phenomenon are complex and multi-factorial, including processes such as decreased tissue sulphydryl availability, reduced bioactivation of the parent drug, physiological compensation and tissue oxidative stress, etc. Munzel et al., 1996; Needleman & Johnson, 1973) . It is presently unknown whether the relaxation eects of NTG on the anorectal tissue are similarly aected by the development of pharmacological tolerance.
The objective of the present study, therefore, was to examine the in vitro and in vivo NTG-induced relaxation response in the anorectal tissue. Speci®cally, we examined (1) the in vivo eects of intra-rectal NTG administration on anorectal pressure, using both bolus and continuous dosing regimens, (2) the presence of pharmacological tolerance incyclic GMP accumulation response in rat aorta vs anorectal tissues after NTG incubation.
Methods

Animal preparation
All procedures were performed according to protocols approved by the Institutional Animal Care and Use Committee, University at Bualo. Male Sprague-Dawley rats, 300 ± 400 g in body weight, were used in the study. When blood pressure measurements were planned, the animal was catheterized 1 ± 2 days before the study at the left femoral artery for blood pressure monitoring, the left femoral vein for bolus drug administration and the right jugular vein for drug infusion (Booth et al., 1996) . On the day of the study, each rat was anaesthetized by intramuscular ketamine 90 mg kg 71 , xylazine 9 mg kg 71 , and this dose was repeated as necessary (generally every 2 ± 4 h). The diuretic eect of anaesthesia was oset by rehydration with intra-peritoneal saline through an implanted 24 ga angiocath. The volume of saline infused was varied according to the observed urinary output, generally totaling around 2 ml every hour administered through several doses.
Measurement of anorectal pressure
Anorectal pressure was monitored via a water-®lled LV balloon made of latex rubber (3 mm diameter, 7 mm length, Kent Scienti®c Corp., CT, U.S.A.) connected through a saline-®lled PE-50 tubing, to a Gould Stathem P23 ID pressure transducer (Ohmeda Inc., NJ, U.S.A.). The pressure signal was recorded on a Grass 79D Physiograph (Grass Instrument Co., MA, U.S.A.) over the 0 ± 50 mmHg range. NTG (Schwarz Pharma, Monheim, Germany, 1 mg ml -1 ) was delivered via a 250 ml-syringe through a PE-10 tubing inserted 7 mm into the anus. The balloon and the tubes were positioned in the anus using small smooth-ended surgical forceps as a speculum to gently dilate the ori®ce. After insertion of the balloon assembly, the system was allowed to reach a stable baseline (generally between 1 ± 1.5 h) before initiation of the experiment. A scheme of the animal preparation is shown in Figure 1 .
Drug administration
In separate experiments, NTG was administered intrarectally either as consecutive bolus doses or as a continuous infusion to the anaesthetized rat. In the bolus dose experiment, each rat (n=6) was given one of the bolus doses (2.5, 5.0, 10.0, 15.0 and 25.0 mg) over 10 s, with each escalating dose separated by a 30-min interval. Anorectal pressure was measured every 5 min for 3 consecutive min after dosing. In the experiment involving continuous NTG infusion into the anorectal cavity, three separate animal groups were infused, either with control (5% dextrose, D5W, n=4), 67 ng min 71 NTG (n=5), or 333 ng min 71 NTG (n=3). The infusion volume (333 nl min
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) was identical for all groups, and was controlled by an electronic infusion pump (Harvard Apparatus, MA, U.S.A.). Anorectal pressure was measured every 30 min during the infusion. It was observed that these infusion volumes did not lead to visible leakage of the dosing solution outside the anus. In additional experiments, animals received continuous i.v. infusion of either 10 mg min 71 NTG (n=4) or D5W (n=5) for 2 h, and the blood pressure and anorectal pressure were monitored simultaneously. To determine the presence of haemodynamic and anorectal NTG tolerance, the mean arterial blood pressure (MAP) and anorectal responses to a 30 mg i.v. NTG bolus were compared before and after NTG infusion. The 30 mg i.v. NTG bolus was chosen because this dose of NTG has been shown to cause near maximal reduction in MAP in rats (E.Q. Wang and H.L. Fung, unpublished data).
In vitro cyclic GMP measurement
The thoracic aorta and the anal canal were collected from anaesthetized untreated rats. The aorta was cleaned of extraneous tissue, and the endothelium was removed by gently rubbing the interior of the lumen with a thin wire. The anal canal was separated into the anal sphincter and the anorectal tissue by visual inspection. The anal sphincter was identi®ed as a muscular strip of pinkish colour, which situated at about 2 mm from the end of the anus. All tissues were incubated with either 0.22 mM NTG or D5W control in Krebs buer at 378C for 1 h in the presence of 0.5 mM 3-isobutyl-1-methylxanthine (IBMX, Sigma Chemical Co., MO, U.S.A.), while being aerated with constant bubbling of 5% CO 2 in O 2 . To lessen the contribution of degraded NTG in solution, the incubation media was changed every 30 min. Following the 1-h NTG incubation, all tissues were rinsed with Krebs buer several times and challenged with 1 mM NTG at 378C for 30 s in the presence of 0.5 mM IBMX, according to the methods of Hasegawa et al. (1999) . Tissues were then immediately frozen in liquid nitrogen and stored at 7808C until cyclic GMP analysis. The frozen tissues were homogenized in 1 ml of ice-cold 6% (w v
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) trichloroacetic acid and centrifuged at 15006g for 15 min. The supernatant was extracted four times with 56volume of water-saturated ether and the aqueous extract was then lyophilized. cyclic GMP content in lyophilized samples was determined using a 
Data treatment
Hard copies of the anorectal pressure tracings at various times after drug treatment were transferred electronically into a graphic computer ®le with a scanner. The area-under-thecontraction-waveforms vs time curve (AUEC, see Figure 2 ) was obtained from these tracings using the NIH free software entitled`Data Thief'. The AUEC per min was recorded over 3 consecutive min, and these triplicate values were averaged to yield a single value of AUEC. To correct for inter-animal variability, AUEC was expressed as per cent baseline AUEC observed in each animal. Correction in baseline anorectal pressure was also carried out, if needed, by connecting thē at parts of the waveforms between each group of rhythmic contraction. When i.v. NTG was administered, the anorectal pressure eect of the 30 mg i.v. NTG bolus was compared to that just before the bolus dose. MAP was calculated as diastolic blood pressure+1/3 (systolic blood pressure ± diastolic blood pressure).
Statistical analysis
One-way ANOVA was used in the anorectal bolus dose study, followed by the Student-Newman-Keuls post-hoc test. Two-way ANOVA was used in the anorectal infusion study to determine statistical dierences between treatment groups (i.e., vehicle control, 66 ng min 71 NTG, and 333 ng min 71 NTG). One-way ANOVA was used to determine, for each treatment, the statistical dierence of the AUEC at various time points vs its own baseline value. Paired Student t-test was used to determine the MAP and anorectal pressure eects of the 30 mg i.v. NTG bolus before and after 10 mg min 71 i.v. NTG infusion. The dierence in cyclic GMP accumulation between D5W and NTG pre-treated tissues was analysed using unpaired Student t-test. Statistical signi®cance was denoted when P50.05.
Results
Figure 2 shows representative 1-min anorectal pressure tracings from a control animal. The top panel presents baseline tracings prior to D5W vehicle infusion, while the second and third panels show tracings after the animal had been infused with D5W (at 333 nl min 71 ) for 30 and 240 min, respectively. It is seen that the pressure waves were somewhat rhythmic but irregular in nature. Typically, the anorectal pressure tracings exhibited 2 ± 3 groups of contractions per min, with each group composed of several waves of contractions. Because of their irregular nature, quanti®cation of the composite contractions was achieved by measuring the area-under-the contraction waveforms over a ®xed time (1 min). This parameter, abbreviated as AUEC, therefore represents an integrated index that re¯ected both the amplitude and frequency of contraction. Thus, the larger the AUEC, the more intense the contraction. The relaxation eect of NTG on anorectal pressure was therefore determined by its ability to lower AUEC. Figure 3 shows representative tracings of anorectal pressure in a rat at baseline (A), 30 min after an intra-rectal NTG bolus dose of 2.5 mg (B, representing a low dose), 10 mg (C, a medium dose) and 25 mg (D, a high dose). It is seen that both the frequency and amplitude of these tracings were substantially reduced with increasing doses of NTG. At the 25 mg NTG bolus dose, the rhythmic anorectal contractions were essentially abolished, even after 30 min. Figure 4 shows the time course of NTG eect on the anorectal pressure after dierent bolus doses of NTG. In the bolus dosing study, ®ve of the six animals responded signi®cantly to NTG dosing, while one animal did not respond to NTG dosing. Since data from the non-responding animal were more than two standard deviations away from the rest of the treatment group, results from this animal were not included in subsequent data analysis. It is evident that at doses above 5 mg rat
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, NTG exerted immediate and sustained decreases in AUEC, indicative of reduction of in vivo anorectal pressure. Although data from the 2.5 mg dose did not exhibit statistical signi®cance from baseline, there were clear trends that even at this dose, NTG could lead to some reduction in anorectal pressure. At the highest dose of 25 mg, NTG still produced 81+10% reduction in anorectal pressure 30 min after dosing. These results strongly indicated that bolus doses of NTG potently reduced anorectal pressure Lack of nitrate tolerance in anorectal relaxation E.Q. Wang et alwhen the drug was introduced into the anorectal cavity. These eects were both immediate and relatively sustained, as well as dose-and time-dependent, at least within the doserange studied. In addition, it was also observed that intrarectal NTG bolus caused a dose-dependent but transient decrease in MAP which quickly returned to baseline within 2 ± 3 min. At the highest dose of 25 mg, a 33.5+2.5% decrease in MAP was observed (data not shown). Figure 5 shows the results of the experiment involving continuous NTG infusion into the anorectal cavity. Continuous infusion of vehicle (D5W) did not cause any change in the AUEC parameter. Infusion of NTG, either at 67 or 333 ng min 71 for 240 min (equivalent to total doses of 16.1 and 79.9 mg, respectively), signi®cantly reduced the AUEC parameter. The eects of NTG were essentially constant from the ®rst point of measurement (30 min) to the end of the experiment (4 h). Two-way ANOVA analysis indicated that both NTG doses produced eects signi®cantly dierent from the vehicle control and from each other (P50.05). It was also observed that intra-rectal NTG infusion did not cause any apparent changes in MAP (data not shown). Figure 6 shows the eects of a 30 mg NTG i.v. bolus challenge dose on MAP and anorectal pressure, before and after 2 h of i.v. NTG infusion (10 mg min 71 ) in the anaesthetized rat. Prior to NTG infusion, the challenge dose produced a substantial decrease (47.2+3.3%) in MAP vs baseline (P50.0001). The peak MAP eect was immediate (within 2 min), but not sustained, and MAP returned to baseline values after 3 ± 5 min (data not shown). However, after 2 h of continuous NTG infusion, the same challenge dose of NTG produced a smaller MAP eect (25.7+3.6%), which was signi®cantly reduced vs pre-infusion values (P50.01).
Prior to NTG infusion, the 30 mg NTG i.v. bolus challenge dose also produced a signi®cant reduction (34.8+5.6%) in Lack of nitrate tolerance in anorectal relaxation E.Q. Wang et alrectal rhythmic contractions, as measured by AUEC (P50.05 vs baseline). After NTG infusion for 2 h, the 30 mg NTG challenge dose produced a similar decrease in AUEC (41.9+15.3%, P40.05 vs AUEC before NTG infusion). Thus, in the same animal, 2-h i.v. infusion of NTG produced a diminished MAP response toward a challenge dose of NTG. In contrast, the anorectal response was maintained under the same conditions (Figure 6 ). D5W vehicle infusion had no apparent eect on the MAP and anorectal relaxation responses of the 30 mg NTG i.v. bolus challenge. Figure 7 shows the results from the in vitro cyclic GMP experiment. NTG pre-treatment of rat aorta for 1 h signi®cantly decreased cyclic GMP accumulation upon NTG challenge, when compared to D5W control (P50.01), consistent with the development of vascular NTG tolerance. Interestingly, in both the anal sphincter and anorectal tissue, NTG pre-treatment not only did not decrease cyclic GMP accumulation upon NTG challenge, but rather slightly increased it when compared to the D5W control. Student ttest revealed that in the anal sphincter, cyclic GMP accumulation from the NTG pre-treated group was signi®cantly higher than the D5W control (P50.01).
Discussion
Our results demonstrated that NTG potently inhibited contraction of the smooth muscle lining the anorectal canal in the anaesthetized rat. The eects were immediate, sustained and dose-dependent. A threshold bolus dose of about 5 mg NTG, when administered intra-rectally to a 300 g rat 71 (about 16.5 mg kg 71 of body weight), produced a sustained 50% reduction in AUEC over the entire 30-min observation period. The relaxation eects on the anorectum of a bolus intra-rectal dose of NTG, however, did dissipate with time (Figure 4 ). This time-dependent loss of eect is likely due to the clearance of the drug from the anorectal site (e.g., from metabolism or distribution of NTG into the systemic circulation). The existence of pharmacological tolerance cannot therefore be answered from the bolus dose experiments (Figure 4 ), but from experiments involving continuous intra-rectal dosing of NTG (Figure 5) , where a constant input dose was applied. Figure 5 shows that two dierent infusion regimens of NTG were able to reduce anorectal contractions continuously, over the 4-h study period. We only carried out our studies to 4 h, since the anaesthetized preparation usually began to show instability after this duration. The continuous relaxation eects produced by NTG in the anorectal region contrasted markedly with the rapid development of haemodynamic tolerance produced by i.v. NTG infusion. Haemodynamic tolerance to the MAP lowering eect of a 30 mg NTG i.v. bolus was observed within 2 h of NTG infusion, while a similar degree of reduction in anorectal pressure was maintained in the same rat (Figure 6 ). It is therefore likely that the mechanisms which govern haemodynamic nitrate tolerance for the cardiovascular system may not be operative in the anorectum, or at least to a much lesser degree.
Unlike the intra-rectal NTG bolus, the anorectal pressure eect produced by an i.v. NTG bolus only lasted for *1 min. This is likely due to a much lower NTG concentration in the anorectum after i.v. administration as compared to the locally applied intra-rectal NTG dose. Newman et al. (1990) reported that in anaesthetized rats, tolerance toward the hypotensive eect of bolus NTG was observed within 1 h of 40 mg kg 71 min 71 NTG infusion. We have shown previously ) that in rats with congestive heart failure, continuous i.v. NTG infusion at 10 mg min 71 produced signi®cant haemodynamic tolerance, as measured by the left ventricular end-diastolic pressure. In normal conscious rats, i.v. NTG infusion at 10 mg min 71 also produced rapid tolerance development to the MAP lowering eect of a 30 mg NTG i.v. bolus dose within 1 h of infusion (E.Q. Wang and H.L. Fung unpublished results).
In order to measure anorectal relaxation in vivo, the use of anaesthetics was unavoidable in our animal preparation. The eects of ketamine and xylazine on anorectal activity have not been explicitly examined. Paskins et al. (1984) have shown that anaesthesia induced by ketamine did not aect the frequency or amplitude of rhythmical activity of the internal anal sphincter. Xylazine is a known a-adrenoceptor agonist (Docherty & Hyland, 1986; Mizobe & Maze, 1995) , so it is possible that anorectal relaxation may be aected by this anaesthetic. We found in this study, however, that administration of a second or third dose of anaesthetics to control animals (which received intra-rectal D5W infusion) did not signi®cantly change the anorectal contraction pattern. Thus, the eects of ketamine/xylazine on anorectal activity are likely to be insigni®cant under our experimental conditions.
Our in vitro data were also consistent with the in vivo results. As expected, prior NTG incubation of the rat aorta signi®cantly reduced cyclic GMP accumulation upon subsequent NTG challenge, consistent with many reports in the literature (Dikalov et al., 1998; Hasegawa et al., 1999) . However, in the anal sphincter as well as the anorectal tissue, prior in vitro NTG exposure did not decrease cyclic GMP accumulation upon NTG challenge. The use of 1 mM NTG as the challenge concentration was based on a previous report by Hasegawa et al. (1999) who showed that this concentration of NTG produces maximal cyclic GMP accumulation in the rat aorta.
We observed an unexpected increase in cyclic GMP accumulation in the anal sphincter after NTG pre-incubation. The mechanism for this observation is currently unknown, but may relate to the experimental design. Since the tissues were incubated in the presence of the phosphodiesterase inhibitor, IBMX, during the 1 h NTG pre-incubation time, the amount of cyclic GMP measured may be a composite of that produced from NTG pre-incubation as well as from the NTG challenge dose. Although cyclic GMP has a very short half-life under normal conditions, its half-life in the presence of a phosphodiesterase inhibitor such as IBMX may be substantially prolonged. The time used to wash tissues with Krebs buer before NTG challenge may not be sucient to remove all the cyclic GMP accumulated during the NTG preincubation.
It is noted that the changes in cyclic GMP accumulation in the anorectal tissue and the anal sphincter were comparatively small when compared to that observed for the aorta in the in vitro study (Figure 7) . It remains to be determined whether cyclic GMP is primarily responsible for mediating the NTG-induced relaxation of anorectal smooth muscle, as it has been extensively demonstrated for the vascular smooth muscle (Fung et al., 1992; Kukovetz & Holzmann, 1983) . It is presently unknown whether other dilative mediators such as cyclic AMP may be additionally involved in mediating NTGinduced anorectal relaxation. Further studies involving determining cyclic AMP accumulation and speci®c inhibition of guanylate cyclase with ODQ, 1H-[1,2,4]oxadiazolo [4,3-a]-quinoxalin-1-one, may be warranted. In recent studies (Tseng et al., 2000) , we showed that NTG-induced relaxation in the rat aorta was signi®cantly reduced by the guanylyl cyclase inhibitor, ODQ. This ODQ inhibition, however, was not reversed by the phosphodiesterase inhibitor zaprinast. In contrast, the ODQ-mediated inhibition of vascular relaxation induced by other NO donors such as sodium nitroprusside and S-nitroso-N-acetylpenicillamine were reversible by zaprinast.
The mechanisms for the apparent lack of tolerance in NTG-induced anorectal relaxation are at present unknown. This tissue may not possess many of the counter-regulatory mechanisms that regulate systemic blood pressure and vascular relaxation, such as the baroreceptor re¯ex or the vascular angiotensin, endothelin and catecholamine systems, which are all thought to contribute to haemodynamic NTG tolerance (Munzel et al., 1996) . The redox state of the anorectal tissue may also be dierent from that of the vasculature and increased oxidative stress induced by NTG (Munzel et al., 1995) may not be operative in this tissue. Further studies are necessary to delineate the apparent dierence in anorectal vs vascular responses to NTG and other organic nitrates.
A limitation of the present study was that the¯uid-®lled balloon assembly for pressure measurement was relatively large, and its lateral apex was placed approximately 5 mm from the anus. Thus, the pressure tracings obtained were unlikely to be derived exclusively from the anal sphincter, and the eects of NTG on in vivo anal sphincter relaxation could not be directly obtained.
In conclusion, our studies have demonstrated that NTG potently inhibited anorectal contractions in the anaesthetized rat, without apparent tolerance development over at least 4 h. These ®ndings are consistent with clinical observations that NTG can be bene®cially used as a ®rst-line therapy in the treatment of anorectal disorders such as anal ®ssures and haemorrhoids.
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